{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-050580","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.884879+00:00","generated_at":"2026-06-10T07:17:26.810034+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Geron's imetelstat MAA for lower-risk MDS validated by EMA for review","bullets":["MAA for imetelstat in transfusion-dependent anemia with lower-risk MDS validated by EMA.","Review by CHMP under centralized procedure covering all 27 EU states plus Iceland, Norway, Liechtenstein.","Expected review period of approximately 14 months.","Submission made in September 2023; now under regulatory review."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-050580","json":"https://secwatch.observer/filing/0000950170-23-050580.json","markdown":"https://secwatch.observer/filing/0000950170-23-050580.md","text":"https://secwatch.observer/filing/0000950170-23-050580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017023050580/0000950170-23-050580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017023050580/gern-20230928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:17:26.810034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}